Cargando…

Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study

BACKGROUND: Treatment for HER2-positive (+) metastatic breast cancer has improved in the last decade. We analyzed treatment changes over time and their impact on patients outcomes in a real-world dataset. METHODS: Data from 637 HER2+ patients with metastatic breast cancer enrolled in the multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Maio, Massimo, Bighin, Claudia, Schettini, Francesco, Ruelle, Tommaso, Marandino, Laura, Fabi, Alessandra, De Angelis, Carmine, Giuliano, Mario, De Placido, Pietro, De Laurentiis, Michelino, Riccardi, Ferdinando, Picotto, Caterina, Puglisi, Fabio, Del Mastro, Lucia, Arpino, Grazia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551556/ https://www.ncbi.nlm.nih.gov/pubmed/37783133 http://dx.doi.org/10.1016/j.breast.2023.103583

Ejemplares similares

Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis
por: De Angelis, Carmine, et al.
Publicado: (2017)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
por: Schettini, Francesco, et al.
Publicado: (2018)

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
por: De Angelis, C., et al.
Publicado: (2021)

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
por: De Angelis, C., et al.
Publicado: (2021)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
por: Schettini, F., et al.
Publicado: (2021)

Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
por: Lambertini, Matteo, et al.
Publicado: (2023)

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
por: Fabi, Alessandra, et al.
Publicado: (2022)

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
por: Schettini, Francesco, et al.
Publicado: (2021)

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
por: D’Arienzo, Andrea, et al.
Publicado: (2023)

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice
por: Buono, Giuseppe, et al.
Publicado: (2022)

GIM and Specialty Medicine
por: Krentz, A J
Publicado: (1999)

GIM and Specialty Medicine
por: Warlow, C P, et al.
Publicado: (2000)

GIM and Specialty Medicine
por: Fleetcroft, R, et al.
Publicado: (1999)

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project
por: Pelizzari, Giacomo, et al.
Publicado: (2018)

Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study
por: Buono, Giuseppe, et al.
Publicado: (2017)

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
por: Puglisi, Fabio, et al.
Publicado: (2021)

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study
por: Buono, Giuseppe, et al.
Publicado: (2020)

Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy
por: Arpino, Grazia, et al.
Publicado: (2015)

Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
por: Arpino, Grazia, et al.
Publicado: (2015)

Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications
por: De Placido, S, et al.
Publicado: (2017)

GIMS—Software for asset market experiments
por: Palan, Stefan
Publicado: (2015)

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
por: Di Lauro, V., et al.
Publicado: (2022)

Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
por: Garutti, Mattia, et al.
Publicado: (2022)

The GIM Mechanism: origin, predictions and recent uses
por: Maiani, Luciano
Publicado: (2013)

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study
por: De Placido, Pietro, et al.
Publicado: (2022)

Comparisons of IRI global TEC maps with CODE GIMs
por: Coisson, P, et al.
Publicado: (2002)

Structural and functional analysis of the GABARAP interaction motif (GIM)
por: Rogov, Vladimir V, et al.
Publicado: (2017)

The Distribution of Incomplete Gastric Intestinal Metaplasia (GIM) Subtype among Biopsy Sites according to the Updated Sydney System and Its Association with GIM Extension
por: Quach, Duc Trong, et al.
Publicado: (2018)

Geneva Innovation Movement (GIM) Arduino Hack at IdeaSquare
por: Poulaillon, Jimmy
Publicado: (2023)

Gimli: open source and high-performance biomedical name recognition
por: Campos, David, et al.
Publicado: (2013)

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
por: Cataldo, Maria Letizia, et al.
Publicado: (2023)

Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention
por: Buonaiuto, Roberto, et al.
Publicado: (2023)

Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients
por: Crispo, Anna, et al.
Publicado: (2023)

Invasin gimB found in a bovine intestinal Escherichia coli with an adherent and invasive profile
por: Matter, Letícia B., et al.
Publicado: (2015)

The Tokyo GIM Conference: Clinical reasoning conference from real cases
por: Watanuki, Satoshi, et al.
Publicado: (2018)

Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer
por: Buonaiuto, Roberto, et al.
Publicado: (2022)

The role of taxanes in triple-negative breast cancer: literature review
por: Mustacchi, Giorgio, et al.
Publicado: (2015)

Rare tumours of the breast
por: Esposito, Emanuela, et al.
Publicado: (2019)

Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
por: Schettini, Francesco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e3lt4hqj6ffcgr71c055f5hmbf